Noemi Reguart
Noemi Reguart
Hospital Clinic Barcelona
Verified email at
Cited by
Cited by
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre …
R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ...
The lancet oncology 13 (3), 239-246, 2012
Screening for epidermal growth factor receptor mutations in lung cancer
R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ...
New England Journal of Medicine 361 (10), 958-967, 2009
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
J Wolf, T Seto, JY Han, N Reguart, EB Garon, HJM Groen, DSW Tan, ...
New England Journal of Medicine 383 (10), 944-957, 2020
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
BBS Zhou, M Peyton, B He, C Liu, L Girard, E Caudler, Y Lo, F Baribaud, ...
Cancer cell 10 (1), 39-50, 2006
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
R Porta, JM Sanchez-Torres, L Paz-Ares, B Massuti, N Reguart, C Mayo, ...
European Respiratory Journal 37 (3), 624-631, 2011
Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma
A Prat, A Navarro, L Paré, N Reguart, P Galván, T Pascual, A Martínez, ...
Cancer research 77 (13), 3540-3550, 2017
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non–small-cell lung cancer patients with EGFR mutations
R Rosell, MA Molina, C Costa, S Simonetti, A Gimenez-Capitan, ...
Clinical Cancer Research 17 (5), 1160-1168, 2011
Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer
J Mazieres, B He, L You, Z Xu, AY Lee, I Mikami, N Reguart, R Rosell, ...
Cancer research 64 (14), 4717-4720, 2004
Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells
L You, B He, Z Xu, K Uematsu, J Mazieres, I Mikami, N Reguart, ...
Oncogene 23 (36), 6170-6174, 2004
DNA repair and cisplatin resistance in non-small-cell lung cancer
R Rosell, RVN Lord, M Taron, N Reguart
Lung cancer 38 (3), 217-227, 2002
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
AMC Dingemans, M Früh, A Ardizzoni, B Besse, C Faivre-Finn, ...
Annals of Oncology 32 (7), 839-853, 2021
Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations
B He, N Reguart, L You, J Mazieres, Z Xu, AY Lee, I Mikami, F McCormick, ...
Oncogene 24 (18), 3054-3058, 2005
Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial
N Karachaliou, C Mayo-De Las Casas, C Queralt, I De Aguirre, B Melloni, ...
JAMA oncology 1 (2), 149-157, 2015
An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth
L You, B He, Z Xu, K Uematsu, J Mazieres, N Fujii, I Mikami, N Reguart, ...
Cancer research 64 (15), 5385-5389, 2004
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression
R Rosell, L Perez-Roca, JJ Sanchez, M Cobo, T Moran, I Chaib, ...
PloS one 4 (5), e5133, 2009
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
R Rosell, U Dafni, E Felip, A Curioni-Fontecedro, O Gautschi, S Peters, ...
The Lancet Respiratory Medicine 5 (5), 435-444, 2017
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
M Duruisseaux, A Martínez-Cardús, ME Calleja-Cervantes, S Moran, ...
The Lancet Respiratory Medicine 6 (10), 771-781, 2018
Assessment of a combined panel of six serum tumor markers for lung cancer
R Molina, RM Marrades, JM Augé, JM Escudero, N Vińolas, N Reguart, ...
American journal of respiratory and critical care medicine 193 (4), 427-437, 2016
Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage iii non–small cell lung cancer: The phase 2 keynote-799 …
SK Jabbour, KH Lee, N Frost, V Breder, DM Kowalski, T Pollock, ...
JAMA oncology 7 (9), 1351-1359, 2021
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
M Majem, O Juan, A Insa, N Reguart, JM Trigo, E Carcereny, ...
Clinical and Translational Oncology 21, 3-17, 2019
The system can't perform the operation now. Try again later.
Articles 1–20